LFMD - LifeMD, Inc.
NASDAQ
->
Healthcare
->
Pharmaceutical Retailers
New York,
United States
Type: Equity
LFMD price evolution
LFMD
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $37.59 | $35.7 | $35.11 | $33.15 |
| Short term investments | ||||
| Net receivables | $6.05 | $5.67 | $5.34 | $5.28 |
| Inventory | $2.65 | $2.06 | $2.37 | $2.76 |
| Total current assets | $48.66 | $45.07 | $44.41 | $42.6 |
| Long term investments | ||||
| Property, plant & equipment | $8.17 | $3.66 | $2.26 | $1.07 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $72.56 | $63.82 | $61.46 | $58.48 |
| Current liabilities | ||||
| Accounts payable | $15.87 | $15.05 | $12.4 | $11.08 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $58.95 | $51.65 | $44.68 | $34.78 |
| Long term debt | $12.95 | $11.8 | $14.07 | $17.93 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $80.28 | $68.03 | $62.3 | $54.98 |
| Shareholders' equity | ||||
| Retained earnings | -$235.37 | -$229.46 | -$221.81 | -$214.27 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.15 | $3.96 | $41.33 | $9.18 |
| Short term investments | ||||
| Net receivables | $5.28 | $2.83 | $0.98 | $0.65 |
| Inventory | $2.76 | $3.7 | $1.62 | $1.26 |
| Total current assets | $42.6 | $11.31 | $44.92 | $12.06 |
| Long term investments | ||||
| Property, plant & equipment | $1.07 | $1.68 | $1.99 | $0.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.99 | |||
| Total investments | ||||
| Total assets | $58.48 | $25.67 | $49.92 | $13.05 |
| Current liabilities | ||||
| Accounts payable | $11.08 | $10.11 | $9.06 | $11.79 |
| Deferred revenue | $0.92 | |||
| Short long term debt | ||||
| Total current liabilities | $34.78 | $31.37 | $22.83 | $13.49 |
| Long term debt | $17.93 | |||
| Total noncurrent liabilities | $0.39 | |||
| Total debt | ||||
| Total liabilities | $54.98 | $32.5 | $23.07 | $13.88 |
| Shareholders' equity | ||||
| Retained earnings | -$214.27 | -$190.56 | -$141.92 | -$80.15 |
| Other shareholder equity | -$2.34 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $53.39 | $50.66 | $44.14 | $44.86 |
| Cost of revenue | ||||
| Gross Profit | $48.38 | $45.64 | $39.54 | $39.5 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $53.07 | $51.94 | $45.72 | $41.68 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.23 | $0.43 | ||
| Interest expense | -$0.56 | -$0.53 | -$0.48 | -$0.62 |
| Net income | ||||
| Net income | -$5.91 | -$7.65 | -$7.54 | -$4.51 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $152.55 | $119 | $37.29 | |
| Cost of revenue | ||||
| Gross Profit | $133.65 | $100.4 | $28.39 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $148.14 | $134.9 | $87.11 | |
| Operating income | -$57.82 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.43 | $0.4 | $0.12 | |
| Interest expense | -$2.6 | -$1.3 | $1.67 | |
| Net income | ||||
| Net income | -$23.7 | -$48.6 | -$58.65 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$8.82 | -$5.32 | -$2.19 | -$8.73 |
| Financing activities | ||||
| Dividends paid | -$2.33 | -$1.55 | -$0.78 | -$3.11 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$2.69 | -$1.86 | -$1.05 | $29.1 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.44 | $2.56 | $1.96 | $29.19 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$60.52 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$12.13 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$8.73 | -$13.91 | -$3.4 | -$0.8 |
| Financing activities | ||||
| Dividends paid | -$3.11 | -$3.11 | -$0.87 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $29.1 | -$0.53 | $68.64 | $21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $29.19 | -$37.38 | $32.15 | $8.07 |
News
Fundamentals
| Market cap | $132.94M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 41.81M |
| Revenue | $193.06M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$25.61M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -5.19 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.69 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.90 |
| EPS | -$0.61 |
|---|---|
| ROA | -39.97% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.83 |
| Quick ratio | 0.78 |